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Pharmacology
from the presence of fluorine at C‑6, which is in the 
left‑sided ring. Fluorine is found in all the modern agents. 
A cyclic diamine R2 usually is present at the 7‑position. 
Some variation is permitted at C‑5 and C‑8. Newer agents 
have had substitutions of amino or methyl at the C‑5 
site. At the 8‑position, numerous small substituents, such 
as fluorine, chlorine and methoxy, has been found to 
improve potency. In general, these antimicrobial agents 
have high bacteriological and clinical cure rates among 
most uropathogens and low rates of resistance among 
common uropathogens.[1]
Ciprofloxacin (CFX) is a second generation fluoroquinolone 
antibiotic introduced to clinical therapy in 1987. 
INTRODUCTION
Fluoroquinolones are most widely used today for the 
treatment of bacterial infections belongs to urinary tract or 
respiratory tract and are considered safe and well‑tolerated 
antibacterial drugs. The name fluoroquinolone comes 
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ABSTRACT
The aim of the study is to examine the oxidative stress in patients on fluoroquinolones (ciprofloxacin, levofloxacin, 
gatifloxacin) therapy for complicated urinary tract infections and to correlate with plasma concentrations at different 
time intervals. Superoxide dismutase (SOD), glutathione, plasma antioxidant status and lipid peroxides were 
evaluated in 52 patients on different dosage regimens up to 5 days. There is significant and gradual elevation 
of lipid peroxide levels in patients on ciprofloxacin (3.6 ± 0.34 nmol/ml to 6.2 ± 0.94 nmol/ml) and levofloxacin 
(3.5 ± 0.84 nmol/ml to 5.1 ± 0.28 nmol/ml) dosage regimen but not with gatifloxacin (3.5 ± 0.84 nmol/ml to 
3.74 ± 0.17 nmol.ml). There was substantial depletion in both SOD and glutathione levels particularly with 
ciprofloxacin. On the 5th day of treatment, plasma antioxidant status decreased by 77.6% %, 50.5%, 7.56% 
for ciprofloxacin, levofloxacin and gatifloxacin respectively. In conclusion ciprofloxacin and levofloxacin induce 
more reactive oxygen species that lead to cell damage than gatifloxacin irrespective of their concentrations in 
patient population. 
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Ciprofloxacin resulted from the replacement of N‑1 ethyl 
group of norfloxacin by cyclopropyl group which resulted 
in extensive anti‑bacterial spectrum[2‑5] and the reason for 
being used widely in variety of human infections.[6] 
Levofloxacin (LVX) is a third generation fluoroquinolone 
antibiotic and is the optical S‑(−) isomer of the racemic 
drug substance ofloxacin. It has a broad spectrum of in vitro 
activity against Gram‑positive and Gram‑negative bacteria, 
as well as certain other pathogens such as Mycoplasma, 
Chlamydia, Legionella and Mycobacteria spp. Levofloxacin is 
significantly more active against bacterial pathogens than 
R‑(+)‑ofloxacin.[7]
Gatifloxacin (GTX) is active against Gram‑positive and 
Gram‑negative organisms, including anaerobes such as, 
Mycoplasma, Chlamydia, and Legionella and mycobacteria.[8‑10] 
Like other quinolones, gatifloxacin penetrates well into 
leukocytes, which can deliver active drug to sites of 
infection and play an important role in the treatment of 
intracellular pathogens.
Nausea, diarrhea, vomiting and similar symptoms were 
the most common side effects noted during therapy 
with fluoroquinolones (0.8% to 6.8%). Central nervous 
system‑related adverse drug reactions vary from mild 
(headache, dizziness, tiredness or sleepiness) to severe 
(psychotic reactions, hallucinations, depression, and 
seizures). The elder patients are susceptible to the central 
nervous system effects of these agents, with dizziness 
being a particular concern. All quinolones have some 
photosensitivity potential including Ciprofloxacin especially 
in higher doses.
During clinical trials, the overall frequencies of adverse 
effects associated with to vary between 4.4 and 20%.[11,12] 
One of the most important concerns is its tendinitis 
potential and rupture of the Achilles tendons. The tendon 
rupture can occur with short‑term use and small dose. 
The pathophysiology of this adverse drug reaction by 
fluoroquinolones is not well known. Several in vitro and in vivo 
study using animals revealed that fluoroquinolones induced 
oxidative stress by producing reactive oxygen species (ROS). 
In vitro studies showed that fluoroquinolones induce an 
early stimulation of the oxidative metabolism in immature 
rabbit chondrocytes[13] and differential effect on newly 
differentiating in vitro human cells.[14,15] Fluoroquinolones 
are capable of modulating oxidative metabolism of 
leukocytes and stimulating the production of reactive 
oxygen species in neutrophils.[16] Perhaps there were no 
studies that could substantiate the role of free radical 
in adverse effects caused by fluoroquinolones in patient 
population and on specified dosage regimen.
The present investigations are focused on studying the 
oxidative stress induced by Ciprofloxacin, levofloxacin 
and gatifloxacin in patients with complicated urinary tract 
infections (UTI), antioxidant status and more importantly 
the effect of dosage regimen.
MATERIALS AND METHODS
All chemicals used in study were of analytical grade. CFX, 
LVX and GTX (Active Pharmaceutical ingredients) were 
obtained from Dr. Reddy’s Laboratories (Hyderabad, 
India). All solvents were HPLC grade. Acetonitrile, acetic 
acid, and methanol were purchased from Rankem (Ranbaxy, 
Mumbai, India. SOD and O‑dianisidine were purchased 
from Sigma St. Louis, USA. Riboflavin was a kind gift 
from Natco Pharma, AP, India. Thiobarbituric acid was 
procured from BDH Fine Chemicals, Mumbai, India. 
CIFRAN® — (Ciprofloxacin 500 mg tablets, Ranbaxy 
(Pharma), LEVOFAN® (Levofloxacin 500 mg tablets, 
Sifam Pharma) GATISTAR® (Gatifloxacin — 400 mg 
tablets, Sifam Pharma) were used in the study.
Instrumentation and chromatography
Analysis of the plasma samples were carried out using 
reported method.[17] Chromatography was performed on 
Prominence (Shimadzu Corporation) HPLC equipment 
consisting of Jasco FP‑920 fluorescence detector, liquid 
chromatography (LC‑10 ADVP), system controller 
(SCL10AVP), a Photo diode array detection (PDA) 
system (SPD‑M 10AVP). A stainless steel Phenomenex 
(C‑18 × 4 mm column, 250 mm, and 0.25 µm) was used 
as stationary phase.
Plasma antioxidant status (PAS) was evaluated using 
specific HPLC method[18] by evaluating the DPPH‑free 
radical scavenging activity in plasma using a LiChrospher® 
100 RP‑18e column (250 × 4 mm, 5 μM). The mobile 
phase was a mixture of methanol and water (80:20, v/v) 
pumped at a flow rate of 1 mL/min. The DPPH peaks 
were monitored at 517 nm. 
The estimation of SOD a free radical scavenging enzyme, 
was performed using the photo oxidation method[19] in 
the hemolysates. To 2 ml of plasma equal volume of cold 
deionized water was added. The mixture was centrifuged at 
3000 rpm for 15 min, and the SOD activity was measured 
in the supernatant. To 0.88 ml of riboflavin solution 
(1.3 × 10−5 mM in 0.01 M potassium phosphate buffer, pH Talla and Veerareddy: Oxidative stress induced by fluoroquinolones
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7.5) 60 μl of O‑dianisidine solution (10 mM in ethanol) was 
added. To this 1 ml of distilled water was added and kept 
away from light. One hundred microliters of the separated 
SOD was added and optical density (OD) measured at 
460 nm using the spectrophotometer. The cuvette was 
then transferred to the illumination box (40 Watt white 
fluorescent tube) for exactly 4 min and the OD was 
remeasured against blank containing ethanol in place of 
enzyme. The SOD was estimated from the standard graph 
plotted using different concentrations of pure bovine SOD.
Plasma concentrations of malondialdehyde (MDA) as 
thiobarbituric acid complexes were measured by HPLC.[20] 
At the beginning of assay, 0.1% butylated hydroxytoluene 
a chain breaking antioxidant was added to prevent the 
peroxidation of lipid. These levels indicate the lipid 
peroxidation and hence the oxidative stress. Glutathione 
was estimated in plasma by the reported method in 
which oxidation of GSH by the sulfhydryl reagent 
5,5'‑dithio‑bis(2‑nitrobenzoic acid) (DTNB) to form 
the yellow derivative 5'‑thio‑2‑nitrobenzoic acid (TNB), 
measurable at 412 nm.[21]
Patient selection
Patient selection was done on randomized basis from 
four tertiary hospitals (Sharanya hospitals) in Warangal 
and Hyderabad, India. All the patients were positive for 
UTI after the confirmation from culture tests (bacterial 
count of more than 10,000 CFU per mL of urine, 
diagnosed as Complicated UTI caused by Escherichia coli, 
Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis or 
Pseudomonas aeruginosaa). The patients selected after doing 
physical examination, electrocardiograms, laboratory 
screening (testing for drugs of abuse, hepatitis and 
human immunodeficiency virus), serology, hematological 
and biochemical parameters. All volunteers had normal 
hepatic, renal functions (mean creatinine clearance of 
112.5 ± 10.4 ml/min/1.73 m2), lipid peroxidation and 
antioxidant status compared to healthy volunteers. 
Further inclusion criteria were as follows: No history 
of gastrointestinal disease or surgery, no medication of 
any kind within 1 week and no alcohol ingestion within 
48 h of study initiation, no allergy or intolerance to any 
drugs (especially to quinolones), no blood donation, and 
no participation in a clinical trial within 60 days of the 
study. These patients did not receive any antibiotics before 
initiation of the treatment with fluoroquinolones.
Total of 52 patients were selected with mean age of 
45 ± 11 years of which 12 were male and 30 were females. 
The dosage regime was 500 mg of CIFRAN thrice a 
day, LEVOFAN 500 mg twice a day and GATISTAR 
400 mg twice a day (standard dosage regimen for treating 
complicated UTI infections). All the medications are given 
orally for 5 days. 16 patients each were on Ciprofloxacin 
and levofloxacin treatment group and other 20 patients on 
gatifloxacin. The study was approved by the Institutional 
Clinical ethics committee (NIPER, Hyderabad, India) 
and written consents were taken from all the patients 
participating in the study.
Blood sampling
Blood sampling was carried out in different phases. 
Five milliliters blood was collected before initiation 
of the therapy and on subsequent days (1st, 2nd, 3rd, 
4th, 5th) day of the treatment. Blood was withdrawn at 
second hour immediately after administering the dose 
of fluoroquinolones on that particular day. Plasma was 
separated immediately with addition of anticoagulant and 
the samples were analyzed for drug concentrations and 
other biochemical parameters mentioned above. 
Data analysis
All the data are represented as mean values ± SD. Statistical 
analysis was performed using a two‑tailed, unpaired 
Student’s t‑test. When multiple comparisons were needed, 
an analysis of variance followed by Student Newman Keuls 
test using Graph Pad Prism (Version 4) was followed. 
Values of P<0.05 were considered significant.
RESULTS
The concentrations indicate either the Cmax (day 1) or the 
CSS (concentrations at steady state for subsequent doses). 
Plasma concentrations of CFX, plasma antioxidant 
status, lipid peroxides, superoxide dismutase (SOD) and 
glutathione at different time intervals are shown in Table  1. 
There is no significant difference in the concentration 
levels either during the loading or maintenance doses. The 
studies indicate a progressive increase in the lipid peroxide 
levels at different days. There is significant increase in the 
lipid peroxide levels from the 1st day (3.6 ± 0.34 nM) to 
5th day (6.2 ± 0.94 nM), which almost doubled. There is 
also significant decrease in SOD (73.3%) and glutathione 
(25.5%) levels with repeated administration of the CFX up 
to 5th day. Plasma antioxidant status (DPPH) decreased by 
77.6% which is considered extremely significant compared 
to levels before initiation of therapy.
Similar results were observed in patient group on 
LVX therapy but moderate decrease in SOD (32.2%), Talla and Veerareddy: Oxidative stress induced by fluoroquinolones
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glutathione (15.2%) and plasma antioxidant status (50.5%) 
as mentioned in Table 2. Lipid peroxide levels increased 
from 3.5 ± 0.84 nM to 5.1 ± 0.28 nM which is considered 
significant. On 5th day, plasma concentration of LVX was 
found to be 5.78 ± 0.45 μg/ml compared to 5.24 ± 0.73 
on day 1. In contrast GTX showed minimal increase in 
lipid peroxide levels. There was an insignificant alteration 
observed in SOD, glutathione and plasma antioxidant 
levels [Table 3]. 
The studies indicate significant disruption of the 
antioxidant status that could be because of the depletion 
of the free radical scavenging enzymes which ultimately 
resulted in elevated lipid peroxide levels. This sequel is 
observed with CFX and LVX but not with GTX.
DISCUSSION
This is the first in human, prospective study to investigate 
oxidative stress of flouroquinolones in pathological 
situation and the effect of dosage regimen. The 
results of this study show that ciprofloxacin and 
levofloxacin have increased the lipid peroxidation 
from 3.6 ± 0.34 nmol/ml to 6.2 ± 0.94 nmol/ml and 
3.5 ± 0.84 nmol/ml to 5.1 ± 0.28 nmol/ml in a time 
dependent manner. The degree of ciprofloxacin induced 
lipid peroxidation seen in this study was comparable to that 
previously reported.[22,23] The effect is greatest 5 days after 
exposure to ciprofloxacin and levofloxacin therapy, which 
indicates the formation of reactive oxygen species as in 
previous studies with fluoroquinolones.[24,25] These results 
further supported by decrease in plasma antioxidant status 
by 77.6% and 50.5% for ciprofloxacin and levofloxacin 
respectively. 
This increase in oxidative stress may be responsible 
for the pathological mechanism of tendinitis due to 
fluoroquinolones.[26] Histological studies have identified 
ultra‑structural abnormalities in tenodocytes and the 
presence of giant cells, the features being similar to those 
of overuse injuries. Animal studies have suggested that 
chelation of magnesium and free radical formation result 
in oxidative stress, leading to a direct toxic effect on 
collagen.[27‑29] The effect of fluoroquinolones on achilles 
Table 1: Plasma concentration of CFX, lipid peroxides, SOD, glutathione and PAS on different days. Values represent 
mean ± SD of 16 patients
Day CFX Con (μg/ml) LP (nmol/ml) SOD (I.U) GLUT (μmol/L) PAS@ (nmol)
0 3.6 ± 0.34 57.23 ± 5.2 86 ± 25 63.4 ± 5.42
1 3.34 ± 0.18 3.8 ± 0.96 42.56 ± 4.89** 402 ± 28*** 51.8 ± 4.98***
2 3.42 ± 0.25 4.2 ± 0.78 30.25 ± 5.55*** 401 ± 30*** 32.6 ± 7.26***
3 3.88 ± 0.34*** 4.8 ± 1.05*** 24.23 ± 5.79*** 398 ± 38*** 20.9 ± 6.84***
4 3.91 ± 0.19*** 5.2 ± 0.87*** 18.34 ± 6.23*** 375 ± 45*** 15.4 ± 4.56***
5  3.88 ± 0.21*** 6.2 ± 0.94*** 15.23 ± 7.01*** 364 ± 41*** 14.2 ± 4.21***
@Equivalent to ascorbic acid. *P<0.05, **P<0.01, ***P<0.001 relative to day 0 for LP, SOD, GLUT, PAS and day 1 for drug concentrations
Table 2: Plasma concentration of LVX, lipid peroxides, SOD, glutathione and PAS on different days. Values represent 
mean ± SD of 16 patients
Day LVX Con (μg/ml) LP (nmol/ml) SOD (I.U) GLUT (μmol/L) PAS@ (nmol)
0 3.5 ± 0.84 59.33 ± 7.45 473 ± 29 60.34 ± 7.89
1 5.24 ± 0.73 3.86 ± 0.46 55.78 ± 5.23 450 ± 21* 58.8 ± 5.42
2 5.68 ± 0.94 3.9 ± 0.56 50.21 ± 5.09*** 420 ± 22*** 49.82 ± 8.56***
3 5.71 ± 0.78 4.2 ± 0.87 50.23 ± 4.77*** 421 ± 34*** 40.54 ± 3.27***
4 5.70 ± 0.97 4.2 ± 0.56* 42.75 ± 4.99*** 400 ± 48*** 38.54 ± 5.85***
5 5.78 ± 0.45 5.1 ± 0.28* 40.75 ± 6.97*** 401 ± 23*** 30.75 ± 8.94***
*P<0.05, **P<0.01, ***P<0.001 relative to day 0 for LP, SOD, GLUT, PAS and day 1 for drug concentrations
Table 3: Plasma concentration of GTX, lipid peroxides, SOD, glutathione and PAS on different days. Values represent 
mean ± SD of 20 patients
Day GTX Con (μg/ml) LP (nmol/ml) SOD (I.U) GLUT (μmol/L) PAS@ (nmol)
0 3.5 ± 0.84 58.34 ± 8.21 486 ± 34 67.44 ± 3.48
1 3.61 ± 0.51 3.66 ± 0.96 58.43 ± 5.72 478 ± 35 62.52 ± 5.33
2 3.81 ± 0.48 3.54 ± 0.44 57.11 ± 7.32 471 ± 46 65.22 ± 8.75
3 3.84 ± 0.39 3.67 ± 0.72 51.34 ± 9.88* 460 ± 41 62.55 ± 8.64
4 3.88 ± 0.69 3.79 ± 0.48 53.37 ± 4.89 470 ± 56 62.89 ± 5.78
5 3.84 ± 0.89 3.74 ± 0.17 54.69 ± 5.37 467 ± 42 62.34 ± 7.89
*P<0.05, **P<0.01, ***P<0.001 relative to day 0 for LP, SOD, GLUT, PAS and day 1 for drug concentrationsTalla and Veerareddy: Oxidative stress induced by fluoroquinolones
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tendon proteoglycans and collagen in rodents showed 
convincingly that quinolone‑induced oxidative stress altered 
proteoglycan anabolism and oxidized collagen. Pefloxacin 
treatment for several days induced oxidative damage of 
collagen type I, with the alterations being identical to 
those observed in the experimental tendinous ischemia 
and reperfusion model.[30]
The efforts of the endogenous antioxidant enzymes like 
SOD to remove the continuously generated free radicals 
initially increase due to an induction but later enzyme 
depletion occurs by 73.3% and 32.2% for ciprofloxacin 
and levofloxacin respectively, resulting in oxidative 
cell damage. Hence when the generation of reactive 
free radicals overwhelms the antioxidant defence, lipid 
peroxidation of the cell membrane occurs. This causes 
disturbances in cell integrity leading to cell damage/death. 
In the present study the repeated administration of 
CFX (recommended dosage regimen of CFX for UTI) 
resulted in increase free radical adduct generation by 
CYP450 mediated metabolism that cumulate and may 
result in increased ROS[26] and substantial reduction in 
antioxidant defence. Perhaps this could be the reason for 
the adverse effect in particular tendinitis attributed to free 
radical generation. The present investigations support 
the pathogenesis of chondrotoxicity explained by the 
magnesium‑chelating properties of these drugs, leading 
to radical formation and finally to irreversible cartilage 
lesions. Animal toxicological studies have been published 
confirming that the quinolone‑induced tendopathy is a 
drug‑induced, dose‑dependent effect of these agents and 
profoundly seen with CFX and LVX.[31]
In vitro studies on tendon cells also report low toxicity 
after 24 hr for all fluoroquinolones, but a high‑significant 
tenotoxicity after 48‑72 hr. Free radical overproduction was 
observed for all fluoroquinolones, but significant anion 
superoxide increased only with pefloxacin and ciprofloxacin. 
Studies separate two models of fluoroquinolones 
tenotoxicity: Pefloxacin or ciprofloxacin induced a higher 
intrinsic tenotoxicity than ofloxacin or levofloxacin.[32] 
A reported hypothesis indicates that, up on administration 
of fluoroquinolones the glutathione content falls rapidly 
so the intracellular antioxidant enzymes lose their ability 
to modulate the overproduction of ROS[33] which was 
also observed in the present study. Gatifloxacin produced 
lesser oxidative stress and can be consider safe relative to 
ciprofloxacin and levofloxacin. 
CONCLUSIONS
There was a considerable increase in lipid peroxide levels 
indicating an enormous oxidative stress. Caution to be taken 
for patients especially on Ciprofloxacin and Levofloxacin 
therapy. These studies necessarily warranty the use of 
exogenous antioxidants as adjuvant in combination with 
fluoroquinolones, and their benefits should be carefully 
examined in a controlled clinical setup.
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